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Should Ischemia
Guide Revascularization?*
William S. Weintraub, MD
Newark, Delaware
Although both coronary artery bypass graft surgery (CABG) and
percutaneous coronary intervention (PCI) are well estab-
lished and frequently performed, decisions concerning re-
vascularization in stable ischemic heart disease (SIHD)
remain difficult. Both forms of therapy should reduce
ischemia, decreasing angina (1–4). In some patients reduc-
tion in ischemia might prevent future cardiovascular events.
Nonetheless, the main diagnostic test that evaluates the
choice of whether to revascularize, the choice between
CABG and PCI, and the extent of revascularization re-
mains coronary arteriography, which evaluates the anatomic
distribution and severity of coronary artery disease, not
ischemia per se. Thus, 3 questions concerning ischemia in
relation to revascularization are raised. Should ischemia guide
the decision of whether to revascularize patients with SIHD?
Should ischemia guide the decision between CABG and PCI?
Should ischemia guide which vessels to revascularize?
See page 181
The paper by Kim et al. (5) in this issue of the Journal
directly addresses the third question, although the inherent
decisions guiding therapy of the patients studied concerns
all 3 questions. This is an observational study of 5,340
patients, of whom 2,587 underwent PCI and 2,753 under-
went CABG. Myocardial perfusion imaging (MPI) was
performed in 42.3%, leading to 12.4% of PCI and 21.8% of
CABG patients undergoing ischemia-guided revasculariza-
tion. The non-ischemia-guided revascularization might be
divided into: 1) those who had MPI ischemia but whose
revascularization did not match the areas of ischemia;
2) those who had MPI but did not have ischemia; and
3) those who did not have MPI. Because this was an
observational study, statistical methods were appropriately
used to reduce confounding. At 5 years, ischemia-guided
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posite of death, myocardial infarction (MI), stroke, and
repeat revascularization in the PCI group but not the
CABG group. This association was entirely due to reduced
repeat revascularization in ischemia-guided patients.
Can this study be used to try to establish whether
ischemia-guided PCI but not CABG causes a reduction in
repeat revascularization compared with non-ischemia-
guided PCI? Furthermore, can this study be used to
establish that ischemia-guided revascularization does not
reduce death, MI, or stroke compared with non-ischemia-
guided revascularization? The answers to both questions are
uncertain. Because this is an observational study, and because
all statistical methods can only correct for observed variables,
there might remain unmeasured or inadequately measured
variables that could confound this set of observations.
The implications of the nature of the mismatch are also
not clear. There might be revascularization of patients in
whom ischemic areas were not revascularized as well as
no-ischemic areas that were revascularized. The latter would
include the small number of patients with normal MPIs that
underwent revascularization. There might also be patients
in the group without MPI in whom revascularization was to
areas that were ischemic, just not demonstrated by testing.
The cleanest comparison might be those with MPI isch-
emia, with and without mismatched revascularization. This
yielded a hazard ratio for ischemia-guided of 0.75 (p 
.13) for revascularization and, interestingly, a hazard ratio
of 0.75 (p  0.046) for death, MI, or stroke. However, the
decision to not revascularize ischemic areas might represent
sound decision making, considering the angiographically de-
fined anatomy. Similarly the decision to revascularize appar-
ently non-ischemic areas might be due to overly enthusiastic
revascularization but also concern, given the angiographic
anatomy, that the MPI represented a false negative.
The MPI scans were not interpreted for reversibility,
meaning that ischemia could not be differentiated from scar.
This is potentially critical, because revascularization of areas
with transmural scar is unlikely to offer clinical benefit.
Thus, such areas in this study—although labeled ischemic—
would appropriately not have been revascularized, biasing
the analysis to the null.
This study is part of a large although certainly not
definitive published data. A critical study concerning how to
guide revascularization was the FAME (Fractional Flow
Reserve Versus Angiography for Multivessel Evaluation)
trial (6). In the FAME trial, 1,005 patients with multivessel
coronary artery disease were randomized to undergo PCI
with and without fractional flow reserve (FFR). The num-
ber of stents placed was 1.9 1.3 and 2.7 1.2 in the FFR
and non-FFR arms, respectively (p  0.001). At 1 year, the
relative risk of death or MI was 0.66 (95% confidence
interval: 0.44 to 0.98) in the FFR compared with non-FFR
arm. Because all patients underwent revascularization, this
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trial, the FAME trial is free of treatment selection bias and
would seem to be more supportive than an observational
study of an ischemia-guided approach.
Should ischemia be used to decide which patients should
undergo revascularization? Observational studies have sug-
gested that patients with ischemia benefit from revascular-
ization (7). However, the benefits of revascularization in
patients with ischemia was perhaps best shown in the ACIP
(Asymptomatic Cardiac Ischemia Pilot) study (8). In the
ACIP study 558 patients with SIHD and ischemia were
randomized to angina-guided (n  183), angina plus
schemia-guided (n  183), or revascularization by PCI or
ABG (n  192). At 2 years, mortality was 6.6% in the
ngina-guided, 4.4% in the ischemia-guided, and 1.1% in
he revascularization strategies (p  0.02). The incidence of
eath or MI was 12.1% in the angina-guided, 8.8% in the
schemia-guided, and 4.7% in the revascularization strate-
ies (p  0.04). In the COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial, however, PCI was shown to decrease ischemia
nd reduce angina but not decrease death or MI (9). Most
atients in the COURAGE trial had demonstrable isch-
mia, although generally not severe. This will be further
ssessed in the ongoing ISCHEMIA (International Study
f Comparative Health Effectiveness with Medical and
nvasive Approaches) trial, which will be targeted to pa-
ients with more severe ischemia than those in the
OURAGE trial. Older studies comparing CABG with
edical therapy show a benefit of surgery in patients with
eft main disease, 3-vessel disease, abnormal left ventricular
unction, and extensive disease on coronary angiography
10–12). Most recently the MAAS II trial (Second Medi-
al, Angioplasty, or Surgery Study) showed a lower inci-
ence of MI in patients randomized to CABG compared
ith medical therapy or PCI (13). Trials and observational
tudies comparing PCI with CABG have not included
valuation of ischemia (14–17).
Because revascularization in SIHD can reduce inducible
schemia and relieve angina, selecting patients for revascu-
arization on the basis of the presence of ischemia would
eem to be appropriate. However, it is not well-established
hich patients benefit by relieving ischemia with revascu-
arization leading to decreased mortality or nonfatal events.
urther data concerning whether ischemia-guided revascu-
arization decreases events will have to wait for the outcome
f the ISCHEMIA trial.
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